IGF1 and Hypoglycemia: While treatment with rhIGF-1 was an obvious first choice, our results in Fig. 9A suggested that, due to constraints of the blood-brain barrier, rhIGF-1 is only able to activate the IGF-1 signaling pathway in the neocortex at dosages reported to produce significant peripheral side effects such as hypoglycemia [59].